MYGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Myriad Genetics Inc (MYGN) is not a strong buy at this time for a beginner investor with a long-term focus. While there are some positive technical indicators, the lack of strong financial performance data, no recent news catalysts, and neutral trading sentiment suggest that this stock does not currently present a compelling investment opportunity.
The MACD histogram is positive and expanding, indicating a bullish trend. RSI is neutral at 60.604, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its pivot level of 4.471, with resistance at 4.698 and support at 4.244.
The MACD is positive and expanding, indicating potential upward momentum. Analysts suggest a steep acceleration in the second half of the year due to HCT momentum, a refreshed sales force, and new product launches.
No significant news in the past week. Analysts have lowered the price target from $7 to $6, reflecting cautious sentiment. Hedge funds and insiders are neutral, with no significant trading trends. Congress trading data is unavailable.
No financial data available to assess the company's latest quarter performance.
TD Cowen lowered the price target to $6 from $7 and maintained a Hold rating. The firm noted Q1 results were light but expects a steep acceleration in the second half of the year.
